rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ABUS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Moderna pressed by US judges on billion-dollar COVID patent defense
      Nov 5ReutersABUSMRNA
      Why Is Arbutus Biopharma Stock Trading Higher Today? - Arbutus Biopharma (NASDAQ:ABUS)
      Oct 22BenzingaABUS
      Arbutus Says US Lifts Clinical Hold on AB-101 Hepatitis B Drug
      Oct 22Yahoo FinanceABUS
      Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

      Arbutus Biopharma is a Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Click for more on ABUS stock.

      Oct 8Seeking AlphaABUSMRNA
      Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

      WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the final results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction, which had a tender price range from US$5.00 per Share to US$5.75 per Share, and

      Oct 1Yahoo FinanceABUS
      Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
      Sep 30Yahoo FinanceABUS
      10 Health Care Stocks With Whale Alerts In Today’s Session - Arbutus Biopharma (NASDAQ:ABUS), Novo Nordis

      This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

      Sep 25BenzingaABUS
      Arbutus launches $230 million share buyback tender offer
      Aug 24Investing.comABUS
      Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

      WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US $5.75 per Share, less any applicable withholding taxes and without inter

      Aug 24Yahoo FinanceABUS
      Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares

      Arbutus Biopharma (ABUS) has commenced a tender offer to purchase for cancellation its common shares

      Aug 24Yahoo FinanceABUS
      Why is Arbutus Biopharma stock surging today?
      Aug 21Investing.comABUS
      Arbutus Gains on $230m Buyback Using Moderna Settlement Proceeds
      Aug 21BloombergABUSMRNA
      Arbutus Biopharma shares jump after unveiling $230 million share buyback plan

      Arbutus Biopharma Corporation (NASDAQ:ABUS) shares climbed 10. 3% in premarket trading on Friday after the biotechnology company announced plans to repurchase up to $230 million of its common stock through a modified Dutch auction tender offer.

      Aug 21Yahoo FinanceABUS
      Arbutus Biopharma stock surges on $230M buyback plan
      Aug 21Investing.comABUS
      Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

      WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75 per share, in cash, less any applicable withholding taxes and without inter

      Aug 21Yahoo FinanceABUS
      Arbutus Biopharma Plans Up to $230 Million Modified Dutch Auction Tender Offer
      Aug 21Yahoo FinanceABUS
      Why Is Arbutus Biopharma Stock Gaining Friday? - Arbutus Biopharma (NASDAQ:ABUS)

      Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.

      Aug 21BenzingaABUS

      This is the newest page. Registered accounts read further back.